Besides, GPR30 selective antagonist G15 could promote the anti-GC effect of NEH, while GPR30 agonist G1 could eliminate this effect, indicating that the GPR30 is important for NEH's anticancer efficacy. Here, GPER1 is linked to gastric cancer.